Robert Schooley, MD, is Professor and Head of the Division of Infectious Diseases of the University of California, San Diego. He has served as Chair of the National Institutes of Health's AIDS and Related Retrovirus 1 Study Section and as Chair of the Executive Committee of the National Institute of Allergy and Infectious Diseases, Adult Clinical Trials Group (ACTG).
About Ardea Biosciences, Inc.
Ardea Biosciences of Carlsbad, California is a biotechnology company focused on the discovery and development of small-molecule therapeutics in virology, oncology and inflammation. The Company has two product candidates in clinical development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is also investigating RDEA806 for the treatment of gout. In oncology, the Company is investigating a mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients. Ardea also is developing a next-generation NNRTI for HIV and a next-generation MEK inhibitor for both cancer and inflammatory diseases.
Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from th
|SOURCE Ardea Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved